Clinical Trial Update: Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pembrolizumab in combination with decitabine and pralatrexate for peripheral T-cell lymphoma and cutaneous T-cell lymphoma; currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Decitabine (Dacogen) (decitabine)
• Pembrolizumab (Keytruda) (pembrolizumab)
• Pralatrexate (Folotyn) (pralatrexate)

Snippet

Sponsor: University of Virginia | Conditions: PTCL, CTCL | Phase 1 | Status: ACTIVE_NOT_RECRUITING